← Eichor
Study identifier: NCT07244016 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Condition: Extensive-stage Small-cell Lung Cancer  ·  Sponsor: Henan Cancer Hospital

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire technology. The study plans to enroll 40 treatment-naive patients with ES-SCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Henan Province Cancer Hospital Ethics Committee Henan Province Cancer Hospital Ethics Committee  ·  0371-65588251  ·  dingjing201305@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Henan Cancer HosipitalZhengzhou, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07244016